Blood Pressure Drug Manufacturer Faces Sanctions Over Discovery

Zhejiang Huahai Pharmaceutical Co. Ltd. will have to pay plaintiffs sanctions after the company’s CEO didn’t appear for a court-ordered deposition, and the company failed to fully comply with discovery requests in litigation over the adulteration of blood pressure drugs.

“It appears that ZHP has sought to benefit from the United States pharmaceutical market but is unwilling to uphold its obligation to abide by US discovery requirements,” Judge Thomas I. Vanaskie, the special master overseeing the litigation in the US District Court for the District of New Jersey on May 10.

The sprawling litigation over blood-pressure drug valsartan and ...